2024-05-21

Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia
SAN DIEGO, May 20, 2024 -- Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of “CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair” in the scientific journal Hernia. The article’s authors are Hanghang Tommy Xu, John ...
2023-06-06

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries
Subjects in Bunionectomy Study Dosed  Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 6, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"),...
2023-05-26

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use
- Subjects in Herniorrhaphy Study Dosed - Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed SAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs in the peri-operative space, announced it has initiated ...
2022-10-17

Cali Biosciences Announces Publication of Phase IIa Results of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue Models Confirming Pharmacokinetics and Safety
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction: Publication of “CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty” i...
2022-07-27

Cali Biosciences Begins and Immediately Fulfills Initial Enrollment for Long-Acting Ropivacaine (CPL-01) Phase II Trial in Bunionectomy
Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase II bunionectomy study of its peri-operative long-acting ropivacaine product (CPL- 01) for post-operative pain control and opioid reduction through 72 hours after bunionectomy.  In a surprise, all slots in the initial cohort of the trial immediat...
2022-03-21

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting analgesic product CPL-01. CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), deve...
2021-11-19

ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) Meeting. CPL-01 is an extended-release injectable version of ropivacaine hydroc...
2021-08-11

Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its perioperative long-acting analgesic product CPL- 01. CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), developed by CaliBio to treat...